Elizabeth Kahn alleged the drugmaker didn’t adequately warn that hair loss, a common side effect of chemotherapy, could be permanent.
Her suit was the second test trial and the second defense win in a multidistrict proceeding in the U.S. District Court for the Eastern District of Louisiana by women alleging they would have chosen a less toxic drug had they known the likelihood of ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.